“TearScience is introducing a revolutionary technology as a new
alternative to traditional treatments for Meibomian Gland Dysfunction,”
said Jeff O’Hara, vice president of sales for TearScience. “Our goal is
to help physicians make a meaningful difference for those who suffer
from chronic evaporative dry eye.”

Herzig Eye Institute of Toronto is one of the first eye care practices
in North America to implement TearScience’s system and has begun
treating patients over the last several months.

Of the more than 100 million dry eye sufferers worldwide, approximately
65 percent have evaporative dry eye. Common symptoms of the disease
include eye irritation, dryness, redness, tiredness, and visual
disturbances.

In a randomized, controlled, multi-center clinical trial involving 139
patients, which compared the LipiFlow® System to iHeat™ warm
compresses therapy for the treatment of Meibomian Gland Dysfunction, the
total meibomian gland secretion score improved in 90 percent of patients
at 4 weeks. Additionally, dry eye symptoms were improved from before the
LipiFlow® treatment in 84-88 percent of patients at four
weeks based on two different recognized symptom questionnaires, Standard
Patient Evaluation of Eye Dryness (SPEED) and Ocular Surface Disease
Index (OSDI).

TearScience will sell its LipiView® and LipiFlow®
devices as a system to eye care practices. LipiView® recently
won the Medical
Design of Excellence Award from UBM Canon.

About TearScience, Inc.

Headquartered in Morrisville, North Carolina, TearScience has pioneered
devices that provide significant clinical improvement in the treatment
of evaporative dry eye. Of the more than 100 million dry eye sufferers
worldwide, approximately 65 percent have evaporative dry eye, which is
caused by Meibomian Gland Dysfunction and a lipid deficiency of the
eye’s natural tear film. TearScience’s integrated, in-office system is
the first to enable eye care professionals to address a root cause of
evaporative dry eye. For additional information, visit www.tearscience.com.